Oppenheimer analyst Jay Olson maintained a Hold rating on 89bio (ETNB – Research Report) today. The company’s shares closed yesterday at $8.70.
Olson covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, ACADIA Pharmaceuticals, and Incyte. According to TipRanks, Olson has an average return of 17.5% and a 43.18% success rate on recommended stocks.
89bio has an analyst consensus of Moderate Buy, with a price target consensus of $30.00, implying a 244.83% upside from current levels. In a report released on May 9, RBC Capital also maintained a Hold rating on the stock with a $13.00 price target.
Based on 89bio’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $34.73 million. In comparison, last year the company had a GAAP net loss of $26.81 million
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ETNB in relation to earlier this year. Last month, Ra Capital Management, Llc, a Director at ETNB bought 1,408,450.00 shares for a total of $7,492,954.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
89bio (ETNB) Company Description:
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
Read More on ETNB:
